MAM
SCLN

Meeder Asset Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Meeder Asset Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-150
Closed -$2K – 1912
2017
Q3 		$2K Buy
150
+8
+6% +$88 ﹤0.01% 1523
2017
Q2 		$2K Hold
142
– – ﹤0.01% 1483
2017
Q1 		$1K Buy
+142
New +$1.42K ﹤0.01% 1630

Meeder Asset Management's SCLN Position: Q4 2017 in Review

Meeder Asset Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 150 shares — an estimated $2K sold.

Meeder Asset Management first reported a position in SCLN in Q1 2017 and held it in 3 quarters. The position peaked at $2K in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

  • Meeder Asset Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • Meeder Asset Management sold 150 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $2K.
  • Meeder Asset Management first reported a position in Sciclone Pharmaceuticals Inc in Q1 2017 and held it in 3 quarters.
  • Meeder Asset Management's Sciclone Pharmaceuticals Inc position peaked at $2K in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on Meeder Asset Management's 13F filing for Q4 2017, filed 2 Feb 2018.